Chitrang Patel1, Raju Dangar2, Yagnik Bhalodia1, Jayesh V. Beladiya2, Vandana R. Thakur2, Anita A. Mehta2*
1Department of Pharmacology, C. U. Shah University, Wadhawan, Gujarat, India
2Department of Pharmacology, L. M. College of Pharmacy, Ahmedabad, Gujarat, India
*Address for Corresponding Author:
Prof. Dr. Anita A. Mehta
Head, Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad-380009 Gujarat, India
Objective: The prevalence of type-2 diabetes mellitus and their complications are rapidly rising all over the globe at an alarming rate. Numerous drugs are available for treatment of diabetes. However, the prominent drug combination is yet not identified for the management of diabetes and its complications. Aim of present study was investigate the effects of PPAR agonist (saroglitazar) alone and in combination with DPP4 inhibitors (Teneligliptin and linagliptin). Materials and Methods: Rats were divided into seven groups (n=8). All the groups except Normal Control (NC) were fed with high fat diet for four weeks, followed by single bolus dose of streptozotocin (STZ, 40mg/kg, i.p.) while NC received vehicle (citrate buffer, 1ml/kg, i.p.). The treatment of saroglitazar (4mg/kg/d, p.o.), teneligliptin (4mg/kg/d, p.o.) and linagliptin (4mg/kg/d, p.o.) were given alone and in combination (saroglitazar (2mg/kg/d) + teneligliptin (2mg/kg/d), and saroglitazar (2mg/kg/d) + teneligliptin (2mg/kg/d)) for 21 days in diabetic rats. At the end of the experiment, various biochemical parameters such as glucose, cholesterol, triglyceride, urea, creatinine, LDH and CK-MB levels were determined in the serum of all rats. Results: The treatment of saroglitazar, teneligliptin, and linagliptin alone; and in combination significantly attenuated serum glucose, cholesterol, triglyceride, creatinine, urea, CK-MB, LDH level in diabetic rats as compared to control rats. However, the protective effects of saroglitazar in combination with DPP4 inhibitors did not show higher significance as compared to the individual therapy. Conclusion: The current study indicated that saroglitazar has additive protective effects with DPP4 inhibitors against diabetes and diabetic complications. However, it did not show the supraadditive effects.
Keywords: Diabetes, saroglitazar, teneligliptin, linagliptin